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Abstract
Background: The 2009 influenza pandemic and shortages in vaccine supplies worldwide underscore the need for new
approaches to develop more effective vaccines.
Methodology/Principal Findings: We generated influenza virus-like particles (VLPs) containing proteins derived from the A/
California/04/2009 virus, and tested their efficacy as a vaccine in mice. A single intramuscular vaccination with VLPs
provided complete protection against lethal challenge with the A/California/04/2009 virus and partial protection against A/
PR/8/1934 virus, an antigenically distant human isolate. VLP vaccination induced predominant IgG2a antibody responses,
high hemagglutination inhibition (HAI) titers, and recall IgG and IgA antibody responses. HAI titers after VLP vaccination
were equivalent to those observed after live virus infection. VLP immune sera also showed HAI responses against diverse
geographic pandemic isolates. Notably, a low dose of VLPs could provide protection against lethal infection.
Conclusion/Significance: This study demonstrates that VLP vaccination provides highly effective protection against the
2009 pandemic influenza virus. The results indicate that VLPs can be developed into an effective vaccine, which can be
rapidly produced and avoid the need to isolate high growth reassortants for egg-based production.
Citation: Quan F-S, Vunnava A, Compans RW, Kang S-M (2010) Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice. PLoS
ONE 5(2): e9161. doi:10.1371/journal.pone.0009161
Editor: Mauricio Martins Rodrigues, Federal University of Sa ˜o Paulo, Brazil
Received September 23, 2009; Accepted January 14, 2010; Published February 11, 2010
Copyright:  2010 Quan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project was supported by Award Numbers R01AI0680003 (R.W.C.), 3R01AI068003-04S1 (R.W.C.) from the National Institute of Allergy and Infectious
Diseases, and partially by the fund from the Georgia Research Alliance (S.M.K.). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: RWC and SMK are inventors on patents on VLP technology, some of which have been licensed. RWC also serves as a consultant or
advisory board member for a company working on VLP vaccines. Because the VLP system reported here is different from VLP vaccine products under
development, the information in this manuscript is only indirectly related to those products. This does not alter the authors’ adherence to all the PLoS ONE
policies on sharing data and materials.
* E-mail: rompan@emory.edu (RWC); skang2@emory.edu (SMK)
Introduction
Influenza is a serious human respiratory disease causing
recurrent outbreaks, significantly affecting human health and the
global economy. In April 2009, several human cases infected with
a novel H1N1 swine-origin influenza virus A (SOIV) were
reported in Mexico and in the United States [1–4]. This virus
spread rapidly to over 74 countries around the world by early June
2009 when the WHO raised the global outbreak alert level to the
pandemic phase 6 [3,5]. WHO regional laboratories reported at
least 12,220 confirmed deaths from the 2009-H1N1 pandemic
influenza virus as of December 27, 2009 (http://www.who.int/
csr/don). SOIV shows an unusually rapid rate of spread, emerging
outside of the normal seasonal period for the virus [2].
Three previous influenza pandemics were caused by the A/
H1N1 virus in 1918 to 1919, A/H2N2 from 1957 to 1963, and A/
H3N2 from 1968 to 1970 [6]. These previous pandemics had
distinct characteristics such as a shift to a new antigenic subtype of
virus, higher mortality in younger populations, multiple pandemic
waves, and higher transmissibility than seasonal influenza.
Influenza A virus infects various host species including birds,
swine, and humans. The new 2009 SOIV (H1N1) virus was found
to contain a combination of gene segments that had not been
previously identified in swine or human influenza isolates [7–9].
The HA, NP, and NS genes of the new 2009 pandemic strain were
derived from classical swine virus and are closely related to the
1918 human pandemic virus. The NA and M genes are from a
Eurasian swine virus. The PB2 and PA genes originated from an
avian virus, and were introduced into the swine viruses. PB1 is
similar to that of human H3N2 virus that acquired the PB1 gene
from an avian virus. There is a concern that further mutation and/
or acquisition of virulence genes derived from other human or
animal influenza viruses could change the new pandemic strain
into a more pathogenic one than it is now [10,11].
Large-scale mass vaccination is the most effective measure to
control the pandemic. However, due to extensive antigenic drift
which occurred in the 2009 pandemic virus, current seasonal
vaccines do not provide any significant cross protection [12]. The
current approach using embryonated hen’s eggs for large scale
virus growth and vaccine manufacture is problematic. During
some recent years, there have been shortfalls in vaccine supply in
response to the influenza season. Local or systemic allergic
reactions to residual egg proteins in the vaccine components can
occur in some individuals. Significant shortages and delays
happened in the supply of the 2009 pandemic vaccine, due in
part to lower growth in egg substrates compared to those observed
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vaccine production that does not rely on the egg supply is highly
desirable particularly for pandemic viruses. Mammalian cell
derived influenza vaccines were found to be immunogenic and
can provide an alternative system for vaccine production [13,14].
Nevertheless, these approaches still rely on growing live viruses for
vaccine production [14]. In contrast, production of virus-like
particles (VLPs) in insect cells can avoid the handling of live
influenza viruses during the vaccine manufacturing process [15].
Also, influenza VLPs were shown to induce broader immune
responses than egg-produced inactivated viral vaccines [16].
In this study, we have investigated the immunogenicity and
protective efficacy of 2009 pandemic influenza VLPs after a single
dose vaccination. Results on protective immune correlates and the
breadth of protective immunity are presented.
Materials and Methods
Virus, Cells and Antibody
H1N1 influenza virus (A/California/04/2009) kindly provided
by Dr. Richard Webby, A/New Caledonia/20/99 virus provided
by Dr. Donald F. Smee, 2009 H1N1 reassortant viruses provided
by Dr. Ruben Donis, and A/PR8/1934 were grown in 11-day old
embryonated hen’s eggs. Egg allantoic fluids were harvested and
stored at 280uC until use. MDCK cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) and used to
determine virus titers from egg allantoic fluids and mouse lung
homogenates by plaque assay. Mice were infected with serial
dilutions of A/California/04/2009 virus and the 50% lethal dose
(LD50) was determined.
Generation of Recombinant Baculovirus (rBV) Expressing
HA and M1 of A/California/04/2009 (H1N1) Virus
A plasmid PCI containing cDNA encoding HA derived from
influenza new H1N1 (A/California/04/2009) was kindly provided
by Dr. Ruben Donis (CDC, Atlanta, GA). The HA gene was PCR
amplified with primers containing flanking restriction enzyme sites
for cloning into the pFastBac plasmid expression vector. (forward
primer, 5- AAA GAATTC ACC ATG AAG GCA ATA CTA
GTA G 3-; reverse primer, 5- TTA CTCGAG TTA AAT ACA
TAT TCT ACA CTG 3-; EcoRI and XhoI sites are underlined).
For M1 gene cloning, A/California/04/2009 virus was inoculated
into MDCK cells and total viral RNA was extracted using an
RNeasy Mini kit (Qiagen). Reverse transcription (RT) and PCR
were performed on extracted viral RNA using the One-Step RT-
PCR system (Invitrogen) with gene specific oligonucleotide
primers. The following primer pairs were used for M1: 5- AAA
GAATTC ACC ATG AGT CTT CTA ACC GAG GT 3-; and 5-
TTA CTCGAG TTA CTC TAG CTC TAT GTT GAC-3.
Following RT-PCR, a cDNA fragment containing the M1 gene
was cloned into the pFastBac vector (Invitrogen). The nucleotide
sequences of the HA and M1 genes were identical to the
previously published sequences (accession numbers FJ966082 for
HA, FJ966085 for M1). Recombinant baculoviruses (rBVs)
expressing HA and M1 of A/California/04/2009 virus were
generated as described previously [17].
Preparation of Influenza VLPs
Sf9 insect cells were co-infected with recombinant BVs
expressing HA and M1, and culture supernatants were harvested
to purify VLPs as described [17]. Characterization of influenza
VLPs was performed by silver staining of sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) as well as
western blot using mouse polyclonal antibodies raised by live
virus infection with the 2009 H1N1 pandemic virus (A/
California/2009) as previously described [18]. HA contents in
purified influenza VLPs were estimated by hemagglutination
activity assay and western blot in comparison with inactivated A/
California/2009 virus. Influenza VLPs were found to contain
approximately 0.1 mg HA (A/California/2009) per 1 mgo ft o t a l
protein of VLPs (,10%), which is a similar level as previously
described for other influenza VLPs [19,20]. For negative staining
of VLPs, sucrose gradient-purified VLPs were applied to a
carbon-coated formvar grid, and the grid was stained with 1%
phosphotungstic acid.
Immunization and Challenge
Female inbred BALB/c mice (Charles River) aged 6 to 8
weeks were used. Groups of mice (12 mice per group) were
intramuscularly immunized with 10 or 0.1 mg (total protein) of
VLPs. For challenge studies, naı ¨ve or vaccinated mice were
isoflurane-anesthetized and intranasally infected with 100 or 10
LD50 of A/California/04/2009 or A/PR/8/1934 virus (10
LD50)i n5 0ml of phosphate-buffered saline (PBS). Mice were
observed daily to monitor changes in body weight and to
record mortality (25% loss in body weight as the Institutional
Animal Care and Use Committee (IACUC) endpoint). All
animal experiments and husbandry involved in the studies
presented in this manuscript were conducted under the
guidelines of the Emory University IACUC. Emory IACUC
operates under the federal Animal Welfare Law (administered
by the USDA) and regulations of the Department of Health
and Human Services.
Antibody Responses and Hemagglutination Inhibition
(HAI) Titer
Blood samples were collected by retro-orbital plexus punc-
ture at week 1, 2 and 5 after immunization, and both sera and
lung homogenates were obtained at day 4 after challenge
infections. Influenza virus specific IgG, IgG1, IgG2a, and IgA
antibodies were determined by enzyme-linked immunosorbent
assay (ELISA) as described previously [18]. As coating antigens
to measure virus specific antibodies, inactivated egg-grown
viruses were coated onto 96-well microtiter plates. HAI titers
were determined using 0.5% chicken red blood cells and 4
HA units per well of A/California/2009, A/PR8 or H1N1
reassortants.
Assays of Lung Viral Titers, Cytokine, and Antibody
Secreting Cells (ASC)
Lung samples, spleens, and bone marrow were collected at day
4 post challenge. Determination of viral titers in lung extracts was
performed using MDCK cells as described [18]. Cytokine
interferon (INF-c) ELISA was performed as described previously
[18]. Ready-Set-Go IFN-c kits (eBioscience, San Diego, CA) were
used for detecting cytokine levels in lung extracts following the
manufacturer’s procedure. For ASC assays, 96-well culture plates
were coated with A/California/04/2009 or A/PR8 virus
overnight, and spleen and bone marrow cells were added to
coated plates after blocking. Secreted antibody levels were
determined after 2 or 6 days in vitro culture.
Statistics
All parameters were recorded for individuals within all groups.
Statistical comparisons of data were carried out using the t-test of
the SigmaPlot (Systat Software, Inc.). A P value less than 0.05 was
considered to be significant.
New H1N1 VLP Vaccine
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Characterization of A/California/04/2009 VLPs
We produced 2009 SOIV VLPs in insect cells co-infected
with recombinant baculoviruses (rBVs) expressing the M1
matrix and HA glycoprotein derived from A/California/04/
09 (H1N1) virus following a procedure previously described
[17]. The incorporation of HA and M1 into VLPs was
confirmed by silver-stained SDS-PAGE (Fig. 1A) and western
blot using immune sera obtained from mice infected with the A/
California/2009 virus (Fig. 1B). HA was found to be one of the
dominant proteins in VLPs (Fig. 1A). HA incorporated into
VLPs was found to be predominantly in the precursor form, and
was found to be cleaved into HA1 and HA2 subunits by trypsin
treatment (Fig. 1C). The hemagglutination activity of the VLPs
(1 mg protein/ml) was found to have approximately 2,560 HA
titers, which indicates the functional integrity of HA incorpo-
rated into VLPs. The size and morphology of the 2009 H1
VLPs resemble influenza virus particles, with spikes on their
surfaces characteristic of influenza virus HA proteins on virions
( F i g .1 D ) .T a k e nt o g e t h e r ,t h e s er e s u l t ss h o wt h a tH 1V L P s
produced in insect cells contained HA with functional activity
and were structurally intact, resembling influenza virions in
morphology and size.
A Single Immunization with 2009 H1 VLPs Elicits
Antibody and HAI Responses
To evaluate VLP immunogenicity, groups of mice (n=12) were
immunized intramuscularly with 10 mg of VLPs (approximately
1 mg HA). We determined the levels of total IgG antibody
responses specific to the A/California/04/2009 and cross reactive
to the antigenically different A/PR/8/1934 virus (A/PR8) (Fig.
2AB) at 1, 3, and 5 weeks after a single immunization with VLPs.
IgG responses specific to the A/California/04/2009 virus and
cross reactive to the PR8 virus increased with time post
immunization (P,0.01), indicating the progressive maturation of
virus-specific antibodies. Even with a low dose of VLP (0.1 mg), a
similar pattern of antibody levels that increased up to 5 weeks after
vaccination was observed (Table 1). Although the difference was
100 fold between high (10 mg) and low (0.1 mg) VLP vaccine doses,
the antibody titers showed only around a 3 fold difference (Fig. 2,
Table 1). As expected, mice immunized with VLPs induced
significantly higher levels of IgG antibodies specific to the
homologous virus by over 60 fold, compared to A/PR8 virus,
which indicates that these two strains are distantly related in terms
of antigenic properties.
IgG2a dominant antibody responses specific to the A/
California/2009 virus were observed in immune sera (Fig. 2C).
Also, significant levels of IgG2a antibodies cross-reactive to A/
Figure 1. Silver stained SDS-PAGE, western blot and electron microscopy examination. (A) Silver stained gel showing HA and M1 bands in
A/California/04/2009 H1 VLPs. M: a standard molecular size marker, Lane 1:2.5 mg of purified influenza VLP protein, Lane 2:1 mg of purified influenza
VLP protein. (B) The incorporation of A/California/04//2009 H1N1 influenza HA or M1 into VLPs (10, 2, and 0.4 mg of total protein) was determined by
Western blot using mouse anti-2009 H1N1 sera or anti-M1 IgG antibody. (C) Cleavage of A/California/04/2009 virus HA in VLPs. VLPs containing HA
(10 mg of total protein) were incubated for 5 min at 37uC with different concentrations of TPCK treated trypsin, resolved by SDS-PAGE, and probed by
Western blotting. The thicker bands of the HA2 subunit are commonly observed after trypsin treatment due to the more effective transfer of HA2
during western blot. Lanes from left to right represent 0, 0.5, 2.5 and 10 mg/ml trypsin respectively. (D) Electron microscopy of influenza H1N1 VLPs.
doi:10.1371/journal.pone.0009161.g001
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sera (Fig. 2D). Taken together with results including total IgG and
the pattern of isotypes induced after a single vaccination, VLPs are
highly immunogenic and can induce virus specific antibody
responses with some cross reactivities.
To investigate immune correlates for predicting protection, we
determined hemagglutination inhibition (HAI) titers in immune
sera collected 1, 3, and 5 weeks after immunization (Fig. 2EF).
Consistent with levels of the pandemic virus-specific antibodies,
the immune sera showed progressive increases in HAI titers up to
250 against the homologous A/California/2009 strain. Impor-
tantly, the HAI titers induced by a single dose of VLP vaccination
were comparable to those obtained by live virus infection with A/
California/2009 (Fig. 2E). As expected, the HAI titers against A/
Figure 2. Humoral responses. A–B: IgG serum antibodies specific to A/California/04/2009 (A) or A/PR8/34 (B) H1N1 influenza virus were
determined at week 1, 3, 5 in the group of mice that were intramuscularly immunized with 10 mg of VLPs. Titers are expressed as the highest dilution
of serum having a mean optical density at 450 nm greater than the mean plus 2 standard deviations above naive serum samples. Significantly higher
IgG titers against A/California/04/2009 or PR8 viruses were detected at week 3 compared to week 1 (P,0.01); and at week 5 compared to week 3
(P,0.001). C–D: IgG2a and IgG1 responses. Serum was serially diluted and ELISA was performed for serum antibodies specific to A/California/04/2009
(C) or PR8 viruses (D). E–F: HAI titers. HAI titers against A/California/04/2009 (E) or A/PR8/34 (F) viruses at week 0, 1, 3 and 5 after a single
immunization were determined. A/California/04/2009 infected sera at 5 weeks after infection were used as control. Significant HAI titers against A/
California/04/2009 viruses were determined at week 5 compared to week 3 or week 1 (P,0.01). Significant HAI titers against A/PR8 viruses were also
determined at week 5 compared to week 1 (P,0.01).
doi:10.1371/journal.pone.0009161.g002
Table 1. IgG antibody responses with low dose (0.1 mg) of
VLPs.
Naı ¨ve week 1 week 3 week 5
150622 400650 64006780 1920062300
IgG serum antibodies specific to A/California/04/2009 influenza virus were
determined at week 1, 3, 5 in the group of mice immunized with low dose 1 mg
of VLPs. Titers are expressed as the highest dilution of serum having a mean
optical density at 450 nm greater than the mean plus 2 standard deviations of
naive serum samples. Significant higher IgG titers against new H1N1 were
detected at week 3 compared to week 1 (P,0.01); and at week 5 compared to
week 3 (P,0.001).
doi:10.1371/journal.pone.0009161.t001
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those against the homologous strain A/California/2009, suggest-
ing that the immune responses preferentially recognize the
homologous vaccine strain. Cross reactive HAI activities were
also determined against seasonal influenza H1N1 virus, A/New
Caledonia/20/1999. The HAI titers were 8–16 with immune sera
collected at weeks 1–5 after vaccination, indicating that cross-
reactive HAI titers against seasonal influenza virus are close to the
background levels.
Interestingly, the VLP vaccine immune sera showed high HAI
titers against reassortant viruses containing HA and NA derived
from pandemic isolates from different geographical sites including
Texas and New York (Table 2), indicating that these isolates are
closely related antigenically. These results indicate that the VLP
vaccines can induce protective functional antibodies to variant
2009 H1N1 isolates at high levels and to an antigenically distant
strain at significantly lower levels.
Protection against Lethal Challenge
To determine the efficacy of a lower vaccine dose, additional
groups of mice were immunized intramuscularly with 0.1 mg VLPs
(approximately 0.01 mg HA) once or twice (weeks 0 and 4), and
then challenged with a lethal dose (10 LD50) of the homologous
virus (A/California/04/2009) at 10 days after the last immuniza-
tion. Since levels of antibody responses were relatively low in the
0.1 mg VLP immunized mice, a lethal dose of 10 LD50 was used
for challenge studies, which is still high enough for testing vaccine
efficacy [18]. Both groups of mice immunized with 0.1 mg VLPs
were protected against lethal challenge (Table 3). The group with
two immunizations displayed no loss in body weight, whereas the
single low dose group exhibited moderate loss in body weight.
Therefore, a dose as low as 0.1 mg of VLPs can provide protection
against lethal infection at as early as 10 days post vaccination even
with a single dose.
To determine the potency of protective efficacies, mice were
challenged with a high lethal dose of A/California/2009 virus (100
LD50) at 6 weeks after a single immunization with VLPs. As shown
in Fig. 3, all naı ¨ve mice died after infection with the wild type A/
California/2009 virus. In contrast, vaccinated mice were com-
pletely protected when challenged with the homologous A/
California/2009 virus and did not show any loss in body weight
(Fig. 3AB). A similar protective efficacy was observed 4 months
after VLP vaccination (data not shown). To determine the
potential cross protection against an antigenically distant strain,
immunized mice were also challenged with A/PR8 virus (10
LD50). VLP immunized mice showed a significant level of
protection, with 75% survival rates against A/PR8 virus, although
the surviving mice exhibited approximately 20% transient loss in
body weight (Fig. 3CD).
The role of immune sera in providing protection was
evaluated in mice that received a lethal dose of virus mixed
with immune or naı ¨ve sera (Fig. 4AB). Immune sera at dilutions
up to 100 fold conferred protection with only a transient body
weight loss whereas a 50 fold dilution provided protection
without any loss in body weight. Higher dilutions of immune
sera did not give any protectiona l t h o u g hb o d yw e i g h tl o s sw a s
d e l a y e dc o m p a r e dt ot h en a ı ¨ve serum control. These results
suggest an important role of humoral responses in providing
protection.
Overall, these results indicate that a single low dose of VLPs can
confer protective immunity against lethal challenge with the new
pandemic virus. Also, influenza VLP vaccines provide some cross
protection against an antigenically distant strain in the mouse
model.
VLP Vaccination Provides Effective Control of Challenge
Virus Replication
The efficiency of virus clearance in lungs provides a sensitive
indicator for assessing protective efficacy. At day 4 post challenge,
mice were sacrificed and viral titers in lung extracts were
determined (Fig. 5A). The naı ¨ve mouse control groups showed
high lung viral titers. In contrast, in mice immunized with VLPs,
A/California/2009 viral titers were below the detection limit
(50 pfu per lung). When the VLP immunized mice were
challenged with A/PR8/1934 virus, a five fold reduction in lung
Table 2. HAI titers against 2009 H1N1 isolates.
Serum Virus strain
1A/California/04/2009
2RG A/Texas/5/2009
2RG A/Texas/5/2009*
2RG A/New York/18/2009
Immune sera 256628 480635 720649 480634
Infected sera 256694 8 0 624 720638 480625
Naı ¨ve sera 860.5 16641 6 641 6 62
HAI titers against different strains of new H1N1 viruses were determined using immune sera collected from mice at week 5 after immunization with A/California/04/
2009 VLP vaccine (immune sera), from mice infected with A/California/04/2009 (infected sera), or naı ¨ve sera.
1Wild type A/California/04/2009 virus.
2Three reassortant
viruses, kindly provided by Dr. Ruben Donis (CDC, Atlanta, GA), were generated with six A/PR/8/34 internal genes and with HA and NA of A/Texas/5/2009, A/Texas/5/
2009* (Q226R mutation in HA), A/New York/18/2009 respectively. Viruses were grown in eggs and used for HAI titers using 4 HA units.
doi:10.1371/journal.pone.0009161.t002
Table 3. Protection of mice immunized with a low dose of
VLPs.
Group Body weight changes (%)
Survival
(%)
D0 D3 D4 D6 D8 D10 D12 D14
Two immunization 100 100 100 100 100 100 100 100 100
Single immunization 100 92 89 88 93 97 98 99 100
Naı ¨v e 1 0 0 9 18 77 5 0
Mice were intramuscularly immunized with 0.1 mg of VLPs once or twice, and
were challenged with a lethal dose of A/California/04/2009 (10 LD50)( n=6 )
day 10 post immunization. Mice were observed daily to monitor changes in
body weight and to record mortality (25% loss in body weight as the IACUC
endpoint).
doi:10.1371/journal.pone.0009161.t003
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the naı ¨ve controls (Fig. 5A).
The H1N1 A/California/2009 virus was found to be lethal to
mice without adaptation although the pathogenesis of this virus
remains largely unknown. To determine whether vaccination
would diminish the production of inflammatory cytokines in lungs,
we determined the levels of interferon c (INF-c) in lung extracts
collected at day 4 post lethal challenge infection. Naı ¨ve mice
infected with A/California/2009 virus showed high levels of IFN-c
(over 300 pg/ml) in lung extracts and eventually all died (Fig. 5B).
The vaccinated mice exhibited 3 fold lower levels (approximately
100 pg/ml lung extracts) of IFN-c compared to those observed in
the naı ¨ve infected control (over 300 pg/ml) but significantly higher
than the uninfected naı ¨ve control, indicating that viral replication
occurred prior to clearance. As a comparison, the A/PR8 infected
naive (unvaccinated) mice exhibited 550 pg IFN-c per ml, and
VLP vaccinated mice were found to have a little decrease in IFN-c
levels after A/PR8 infection (Fig. 5C). Therefore, these results
indicate that VLP vaccination can confer effective control of
viral replication, resulting in reduced proinflammatory cytokine
production.
VLP Vaccination Induces Effective Recall Immune
Responses
A goal of vaccination is to confer the host with immunity to
respond rapidly upon encounter with a pathogen. As a measure of
recall immune responses, we compared the immune responses
before and after challenge infection. Virus specific antibody
responses over background were not found in lungs and sera of
naı ¨ve mice at 4 day post challenge with A/California/2009 virus
(data not shown). VLP vaccinated mice showed high levels of lung
IgG antibodies specific to the homologous virus, and their levels
were similar before and after challenge (Fig. 6A). Lower levels of
lung IgA antibodies were observed after challenge compared to
those before challenge (Fig. 6B, P,0.05 before and after
challenge).
In contrast to lung antibodies, significant higher levels of serum
IgG and IgA antibody responses were detected at day 4 post
challenge with the homologous A/California/04/2009 (Fig. 6C
and 6D) compared to those before challenge. Serum IgG antibody
levels specific to the homologous virus were 60 and 15 fold higher
than those specific to the antigenically different A/PR/8/1934
virus at the time of before and after challenge respectively (data
not shown). Nonetheless, it is interesting to note that IgA
antibodies were found to be induced in sera of mice systemically
vaccinated with VLPs. Overall, these results indicate that VLP
vaccination can confer effective recall immune responses, which
are likely to contribute to protective immunity.
To determine the antibody secreting cell responses, spleen
cells were harvested at day 4 post challenge infection and
subjected to in vitro culture. After 2-day’ cultures, high levels of
antibodies specific to A/California/2009 viral antigens were
Figure 3. Protection of mice from lethal influenza virus challenge. A–B: Protection against A/California/04/2009 virus challenge. Mice
intramuscularly immunized with a single dose of VLPs (10 mg) were challenged with a lethal dose (100 LD50) of A/California/04/2009 virus at week 6
post immunization. Mice (n=12) were monitored daily for 14 days for body weight changes (A) and survival rates (B). C–D: Protection against the
antigenically distant A/PR8/1934 virus (10 LD50). Body weight changes (C) and survival rates (D) are shown.
doi:10.1371/journal.pone.0009161.g003
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vaccinated with VLPs but not from unvaccinated mice
(Fig. 7A). Antibodies specific to A/PR8/1934 viral antigen
were also found to be secreted at low levels after 6 days of in
vitro culture (data not shown).
When we analyzed antibody secreting cell responses in the bone
marrow where long-lived plasma cells reside, high levels of A/
California/2009-specific antibodies were found to be secreted into
bone marrow culture supernatants (Fig. 7B). Similar levels of
antibody secreting cell responses were observed before challenge
(data not shown). In summary, these results suggest that a single
vaccination with VLP vaccines can induce antibody secreting
plasma cell responses at an early time point post challenge
Figure 4. Protective role of immune sera. Naive sera from
unimmunized mice or immune sera from vaccinated mice (10 mg VLP
single dose) were serially diluted (1X, 50X, 100X, 500X, and 2500X or
naı ¨ve sera). These diluted serum samples (20 ml) were mixed with 40 ml
of A/California/04/2009 virus (10 LD50) and incubated for 30 min at
30uC. Mice (n=4 BALB/c mice per each diluted serum-virus group) were
intranasally infected with an in vitro incubated mixture of naı ¨ve or
immune sera and A/California/04/2009 virus (10 LD50), and monitored
daily for 14 days for body weight changes (A, B). Survival rates (C). The
numbers in the parenthesis indicate survival rates in each infected
group.
doi:10.1371/journal.pone.0009161.g004
Figure 5. Lung virus titer and inflammatory cytokine IFN-
gamma. (A) Lung virus titers. Lung samples from individual mice
immunized with 10 mgV L P si ne a c hg r o u p( n=6 )w e r ec o l l e c t e do n
day 4 post-challenge with a lethal dose of A/California/04/2009 or A/
PR8/1934 virus. Each lung sample from a mouse was suspended in
1 ml with Dulbecco’s modified Eagle’s medium. Statistical signifi-
cance is indicated between groups of mice challenged with A/
California/04/2009 (P,0.001) or A/PR8/34 (P,0.01) compared to
n a i v em i c ec h a l l e n g e dw i t ht h es a m el e t h a ld o s e .( B )L u n g
inflammatory cytokine IFN-c after A/California/04/2009 challenge.
(C) Lung inflammatory cytokine IFN-gamma after A/PR8/1934
challenge. H1N1 Cha, VLP immunized mice after A/California/04/
2009 challenge, N+H1N1 Cha: Naı ¨ve mice after A/California/04/2009
challenge, PR8 Cha: VLP immunized mice after A/PR8/1934 challenge,
N+PR8 cha: Naive mice after A/PR8/1934 challenge. Naı ¨ve: Untreated
mice.
doi:10.1371/journal.pone.0009161.g005
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can rapidly differentiate into antibody secreting plasma cells upon
exposure to a pathogen.
Discussion
The ongoing, rapidly spreading influenza pandemic to which
the human population has little immunity is a great public health
concern particularly for children and young adults. Intramuscular
vaccination is the common delivery route for most vaccines
including influenza. In the present study, we tested the
immunogenicity and protective efficacy of pandemic VLPs after
a single dose intramuscular vaccination. We found that vaccinated
mice were completely protected against challenge infection with a
high lethal dose of the A/California/2009 virus, and that viral
replication in the lung was reduced to levels below the detection
limit. The insect cell expression system provides an alternative
approach for scaling-up mass production of vaccines. VLPs
containing biologically active glycoproteins from different influ-
enza subtypes have been previously produced in insect cells and
have been shown to elicit strong immune responses conferring
protection against homologous or related heterologous viruses
[18,21,22].
Most previous studies have focused on immune responses and
protection induced after a prime-boost immunization regimen. It
is significant, as demonstrated in this study, that a single
intramuscular dose of VLPs can provide complete protection
against a high lethal dose (100 LD50) of wild type A/California/
2009 virus with no detectable viral titers in the lung, the major site
for viral replication. In a dose sparing test, a very low dose of VLPs
(,0.01 mg HA) was also found to provide protection against lethal
infection as early as 10 days post vaccination. Even at week 5 post
single vaccination with a low dose when antibody levels were
higher than those at day 10 (Table 1), these mice still showed a
moderate loss in body weight (data not shown). The boost
vaccination has significantly improved protection efficacy without
showing any body weight loss. These results indicate that VLPs are
an attractive vaccine platform, possibly because of their particulate
nature as well as the presentation of functional glycoproteins in a
native conformation. Also, there is a high possibility that
suspended culture of insect cells is relatively easy to be expanded
to a large fermentation reactor scale with a competitive production
cost.
Previous studies demonstrated that intranasal immunization
with inactivated whole viral vaccines could induce heterosubtypic
immunity in the presence of heat-labile enterotoxin or cholera
toxin adjuvants using a prime-boost vaccination regimen [23–25].
However, there are concerns about potential adverse effects
regarding the use of endotoxin adjuvants [26,27]. A recent study
has shown that two intramuscular immunizations with chimeric
influenza VLPs containing a membrane-bound form of bacterial
flagellin induced partial protection against a heterosubtypic virus
challenge [28]. Induction of HA specific antibodies as well as high
HAI titers is likely a major contributor to protection and effective
clearance of virus, which was shown by the protective role of
antibodies induced by VLPs. The same immune sera also showed
low HAI titers cross reactive to A/PR8 virus, a 1934 isolate. The
amino acid sequence homology between A/California/2009 and
A/PR8/1934 is only 74.3% in the HA1 subunit, which is the
major site determining antigenicity. Therefore, the present study
Figure 6. Recall antibody responses in lung and serum. Lung IgG (A) and IgA (B), and serum IgG (C) and IgA (D) antibody responses to A/
California/04/2009 virus were determined before (week 6.5 post immunization) and after challenge (day 4 post challenge) with the homologous virus
A/California/04/2009. Lung and serum samples before and after challenge were collected at the same time (n=6) and analyzed under the same assay
condition (week 6.5 post-vaccination). Lung IgA (B) before and after challenge: P,0.05. Serum IgG (C) and IgA (D) responses before and after
challenge from the A/California/04/2009 virus challenge: P,0.001. Low and moderate naı ¨ve backgrounds were observed in the serum and lung
samples respectively and these values have been subtracted from the immune samples.
doi:10.1371/journal.pone.0009161.g006
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vaccine in the absence of adjuvant can induce complete protection
against the homologous virus, as well as partial protection against
a distantly related strain, has significant implications for future
vaccine strategies to overcome antigenic variation.
Due to the sequence variation between the 2009 pandemic and
antigenically distant A/PR/8/1034 or seasonal influenza virus A/
New Caledonia/20/1999, levels of cross reactive HAI titers to
these viruses were relatively very low, which might not be
protective. Thus, other immune factors might have contributed to
the partial cross protective immunity, which may include the
IgG2a and IgA antibody responses as well as T cell immune
responses although this remains to be determined. The dominant
IgG2a isotype antibody responses and the induction of rapid recall
antibody-secreting cells are likely to play a role in the effective viral
clearance and homologous protection as well as partial cross
protection by the VLP vaccination. IgG2a isotype antibody is
known to be more effective than other isotypes in clearing virus
infection via multiple mechanisms including complement activa-
tion, stimulation of antibody-dependent cellular cytotoxicity and
clearance of opsonized virus by macrophages [29–31]. Vaccinated
mice showed high antibody levels in sera at day 4 post challenge,
which is consistent with the generation of antibody secreting cells
in spleen and bone marrow.
In conclusion, this study demonstrates highly effective immunity
to the new pandemic virus by VLP vaccination, resulting in
effective viral clearance and protection. VLP vaccines have
advantages in vaccine production, not requiring fertilized egg
substrates. Therefore, development of influenza VLP vaccines
should have a significant impact on control of influenza.
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